Volume 33

Number 7

March 30, 1994

Inorganic Chemistry

*⁰*Copyright *1994* by the American Chemical Society ^I

Communications

Lipophilic Hexadentate Aluminum, Gallium, Indium, and Iron Complexes of a New Phenolate-Derivatized Cyclohexanetriamine Ligand

James E. Bollinger, Joel T. Mague, and D. Max Roundhill'

Department of Chemistry, Tulane University, New Orleans, Louisiana **701 18**

Received January *21, 1994*

The coordination chemistry of the group 13 (IIIA) metal ions is of biomedical interest because of the association of aluminum with neurological dysfunctions' and also because of the use of gallium and indium radioisotopes for imaging applications.2 Gallium and indium are potentially useful as radiopharmaceutical imaging agents because the isotopes ⁶⁷Ga, ⁶⁸Ga, ¹¹¹In, and ¹¹³In have the appropriate energies and half-lives for either γ -ray imaging or positron emission tomography. In order for these isotopes to be selectively transported in solution to the in vivo target, one of the necessary prerequisites is that their complexed trivalent ions remain tightly bound to a carrier ligand. High binding constants for metal ions are generally obtained with multidentate hard ligands, and for the particular cases of Ga- (111) and In(II1) the phenolate anion is a strongly coordinating ligand.³

In this communication we report the synthesis of a new hexadentate ligand that is specifically designed for complexation with a trivalent metal ion and the characterization of waterstablecomplexeswith **Al(III),Ga(III),In(III),and** Fe(III).These ligands have phenolate groups appended to a cis-cyclohexanetriamine backbone, and they are among the first examples of a nonmacrocyclic hexadentate ligand that is specifically designed for complexation with these trivalent metal ions.4 These ligands have phenolate groups appended to a cis-cyclohexanetriamine backbone, and they are among the first examples of a nonmacrocyclic hexadentate ligand that is specifically designed for complexation with these trivalent metal ions.4 The ligands have been designed to avoid the presence of the $C=N$ functionality since it is believed to undergo in vivo degradation.⁵ The ligands are designed to yield uncharged complexes when coordinated to a trivalent metal ion in order that they can potentially be used

^a Key: (a) PhO₂SCl, pyridine, 10 °C; (b) NaN₃, diethylene glycol, 100 °C; (c) LiAlH4, THF, reflux; (d) salicylaldehyde, EtOH, reflux for 1a and 5-nitrosalicylaldehyde, EtOH, reflux for 1b; (e) KBH₄, EtOH, reflux.

to prepare Ga(II1) and In(II1) myocardial perfusion agents.6 These new uncharged hexadentate complexes of Al(III), Ga- (111), and In(II1) are soluble and stable both in aqueous solution and in organic solvents such as benzene, alcohols, and diethyl ether. As a measure of the lipophilicity of these complexes, the 1-octano1:water partition coefficients have the respective values of **9.0, 8.4, 49,** and 13 for Al(L), Ga(L), In(L), and Fe(L) (L $=$ hexadentate ligand 1b).

The synthesis of these new hexadentate ligands first involves the transformation of **cis-l,3,5-cyclohexanetrio1** into cis-l,3,5-

Liu, **S.;** Rettig, **S.** J.; Orvig, C. *Inorg. Chem.* **1992,31,5400-7.** Banks, W. A.; Kastin, A. J.; Fasold, M. B. *J. Pharmacol. Exp. Therapeutics* **1988,244,579-85.** Banks, W. A.; Kastin, A. J. *Neurosci. Behav. Rev.* **1989**, *13.* **47–53**

Hoveyda, H. R.; Karunaratnc, V.; Rettig, **S.** J.: Orvig, C. *Inorg. Chem.* **1992, 31, 5408-16.**

Motekaitis, R. J.; Marteil, A. E.; Welch, M. J. Inorg. *Chem.* **1990, 29, 1463-7.**

Uncharged gallium complexes with macrocyclic or pyramidal ligands of type N303 and N& have, however, been synthesized. **See:** Moore, D. A.; Fanwick, **P.** E.; Welch, M. J. *Inorg. Chem.* **1990,29,672-6.** Liu, *S.;* Wong, **E.;** Rettig, **S.** J.; Orvig, C. Inorg. *Chem.* **1993,32,4268-76.** Liu, *S.;* Gelmini, L.; Rettig, **S.** J.; Thompson, R. C.; Orvig, C. J. *Am.*

Chem. SOC. **1992,114,6081-7.**

⁽⁶⁾ Green, **M.** A.; Mathias, C. J.; Neumann, W. L.; Fanwick, **P. E.** Janik, M.; Dcutsch, E. A. *J. Nucl. Med.* **1993, 34, 228-33.**

Figure 1. ORTEP representation of the structure of Al(L).

cyclohexanetriamine using the method of Fleisher.^{7,8} This procedure involves converting the triol to the tris(benzenesulfonate), followed by substitution with azide ion and reduction to the amine with lithium aluminum hydride. *(Caution! Polyazides arepotentially explosive.)* Condensation of *cis-* **1,3,5** cyclohexanetriamine with salicylaldehyde or 5-nitrosalicylaldehyde,⁹ followed by the reduction of the resulting Schiff base with potassium borohydride, gives the respective cis-tris((hydroxybenzyl)amino)cyclohexane products 1a,b (Scheme 1).¹⁰ The NO₂ group has been appended because it allows for changes to be made in the lipophilicity of the complex and also because it offers a potential binding site for attachment to an antibody *via* an isothiocyanate group.11 Complexes of **lb** (L) have been obtained with the Al(III), Ga(III), In(III), and Fe(II1). Complexation is achieved by dissolving the metal nitrate or chloride in absolute ethanol along with an equimolar amount of the L.3HC1, followed by addition of an excess of noncoordinating base such as **diisopropylethylamine.l2** Upon refluxing of the solution, the complexes precipitate. The complexes have been characterized in solution by a combination of IR, NMR, and UV spectroscopy. The X-ray crystal structures of the $AI(L)$ and $Fe(L)$ complexes confirm that they have an uncharged monomeric structure in the

- (7) Fleisher, E. B.; Gebala, A. E.; Levey, A.; Tasker, **P.** A. *J. Org. Chem.* **1971,** *36,* 30424.
- **(8)** We find that this route to **cis-1,3,5-cyclohexanetriamine** from cis-1,3,5 cyclohexanetriol is more reliable than the published procedure via the reduction of the trioxime of phloroglucinol with sodium in liquid ammonia (Lions, F.; Martin, K. **V.** *J.* Am. *Chem.* **SOC. 1957,** *79,* 1572-5).
- (9) Rudman, D. A.; Huffman, J. C.; Childers, R. F.; Streib, W. E.; Wentworth, R. A. D. *Inorg. Chem.* 1975, 14, 747-51.
(10) Anal. Calcd for $C_{27}H_{39}C_{13}N_6O_{12}$: C, 43.5; H, 5.28; N, 11.3; O, 25.7 (m/e 583). Found:
- (FAB)). Spectral data for 1b-3HCl are as follows. IR (KBr) (cm⁻¹): v(NH) 2900-3100, br, w; 6(NH) 1593, **s;** 5123, **s;** u(N02) 1496, m; 1338, **s.** IH NMR (CDC13): **6** 1.8 m (3H), 2.74 m (3H), 3.33 m (3H), 4.20 m (6H), 7.18 d (3H), 8.18 d (3H), 8.47 **s** (3H), 9.65 bs (lH), 12.1 bs (3H). ${}^{13}C[{}^{1}H]NMR$: δ 30.3, 52.6, 42.4, 119.7, 139.6, 116.2, 127.1, 163.1, 128.5
- (11) Brechbiel, M. W.; Gansow, O. A.; Atcher, R. W.; Schlom, J.; Esteban, J.; Simpson, D. E.; Colcher, D. *Inorg.* Chem. **1986,** *25,* **2772.**

solid state.¹³ The distances and angles within the structures do not indicate the presence of any significant strain.

An ORTEP representation of the Al(L) complex is shown in Figure 1. The corresponding iron complex is isostructural. Both complexes crystallize with a molecule of ethanol which is weakly hydrogen bonded to one metal-coordinated oxygen atom of the ligand. The crystal structure has the metal in an octahedral coordination environment with the ligand acting as a hexadentate species. This results in the creation of a network of skewed sixmembered rings such that each oxygen moiety is *trans* to the amine of a neighboring pendant arm. In Figure 1 two of the pendants assume a propeller-like conformation while the third does not, reflecting an inversion of one six-membered ring as compared to the other two. The **'H** NMR spectra indicate that the threecoordinating pendants are equivalent **on** the NMR time scale and the structure is semirigid. This feature is evident from the presence of distinct and separate resonances for the two pendant methylene protons individually coupled to the adjacent amine proton. *In vivo* studies with these ligands and complexes are presently underway.

Acknowledgment. We thank the Center for Bioenvironmental Research for financial support.

Supplementary Material Available: Text giving details of the data collection and structure solution and tables of crystallographic data, positional parameters, bond distances, bond angles, and general displacement parameters for Al(L) and **Fe(L)** (32 pages). Ordering information is given on any current masthead page.

 $= 1.49 \text{ g cm}^{-3} (1.44 \text{ g cm}^{-3})$, $Z = 4$ (4). From 2672 (3105) unique reflections with $I \ge 2\sigma(I)$ out to 25 °C (Mo Ka) the structure was solved by direct methods and refined with anisotropic thermal parameters to $R = 4.5\%$ (4.0%) and $R_w = 4.9\%$ (4.7%). A), $c = 20.540(2)$ A (20.229(3) A), $V = 3042(2)$ A³ (3005(1) A³), ρ_{calc}

⁽¹²⁾ Data for Al(L)-C₃H₆O are as follows. Anal. Calcd for $C_{30}H_{33}N_6O_{10}$ -Al: C, 54.2; H, 5.02; N, 12.7 (m/e 607). Found: C, 54.4; H, 5.32; N, 12.6 (m/e 607(1) (FAB)). IR (KBr) (cm⁻¹): $\nu(NH)$ 3246, w; $\delta(NH)$ 1601, m; $\nu(NO_2)$ 1482, s; 1332, s. ¹H NMR (CDCl₃): δ 1.83 b (3H), 2.56 b (3H), 3.03 bs (3H), 3.34 b (3H), 4.13 t (3H), 6.21 d (3H), 7.99 d (3H), 7.94 s (3H), 5.31 b (3H). UV (MeCN): λ_{max} 360 nm (4.59 \times 10⁴), 238 nm (1.32 × 10⁴). Data for Ga(L) \cdot H₂O are as follows. Anal. Calcd for C₂₇H₂₉N₆O₁₉Ga: C, 48.8; H, 4.41; N, 12.7 *(m/e 636).* Found: C, 48.8; H, 4.53; N, 12.9 *(m/e 636)1* (FAB)). IR (KBr) (cm-I): v(NH) 3244, w; 6(NH) 1601, m; v(NO2) 1482, **s;** 1332,s. IH 4.24 t (3H), 6.26 d (3H), 7.96 d (3H), 7.95 **s,** 5.58 b (3H). **UV** (MeCN): λ_{max} 366 nm (4.57 × 10⁴), 226 nm (1.60 × 10⁴). Data for In(L)·H₂O are as follows. Anal. Calcd for C₂₇H₂₉N₆O₁₀In: C, 45.5; H, 4.11; N, 11.8 *(m/e 6*95). Found: C, 45.8; H, 4.46; N, 11.7 *(m/e* 695(1) (FAB)). IR (KBr) (cm-1): v(NH) 3244, w; 6(NH) 1599, m; (3H), 3.23 b (3H), 3.39 b (3H), 4.37 t (3H), 6.48 d (3H), 7.96 d (3H),
7.99 s (3H), 5.56 b (3H). UV (MeCN): λ_{max} 368 nm (5.70 × 104), 234 nm (1.54 \times 10⁴). Data for Fe(L) \cdot H₂O are as follows. Anal. Calcd for C2,HsNsOloFe: C, 49.6; H, 4.48; N, 12.9 *(m/e* 649). Found: C, 49.4; H, 4.95; N, 12.72 (m/e 649(1) (FAB)). IR (KBr) (cm⁻¹): $\nu(NH)$
3238, w; $\delta(NH)$ 1597, m; $\nu(NO_2)$ 1491, s; 1336, s. UV (MeCN): λ_{max}
500 nm (2.99 × 10³), 368 nm (4.04 × 10⁴), 240 nm (1.73 × 10⁴).
0 Crystall NMR (CDCI3): 6 1.86 b (3H), 2.60 b (3H), 3.14 b (3H), 3.37 b (3H). v(N02) 1491, **S;** 1336, **S.** 'H NMR (CDCI,): **6** 1.89 b (3H), 2.56 b